AI Article Synopsis
- The study evaluated whether hematopoietic progenitor cell (HPC) counts from a Sysmex analyzer can replace flow cytometric CD34+ cell analysis for timing apheresis in stem cell donation.
- HPC counts of ≥24 × 10/L in healthy donors and ≥36 × 10/L in lymphoma patients were found to predict adequate mobilization with 100% accuracy, potentially reducing flow cytometry analyses significantly.
- In multiple myeloma patients, a higher HPC threshold was necessary due to bias, but still allowed for some reduction in flow cytometry analyses, emphasizing the need for confirmation when HPC counts are lower.
Article Abstract
Background: The reference method for hematopoietic stem cell enumeration is flow cytometric CD34+ cell analysis. We evaluated using the hematopoietic progenitor cell (HPC) count on the Sysmex hematology analyzer to safely replace some flow cytometric measurements performed in peripheral blood samples to guide apheresis timing.
Study Design And Methods: We compared HPC and CD34+ cell counts in 133 preharvest peripheral blood samples and 124 apheresis products.
Results: Pre-apheresis HPC counts ≥24 × 10/L in healthy donors and ≥36 × 10/L in lymphoma patients predicted adequate mobilization with 100% specificity and positive predictive value, saving 79% and 63% of flow cytometry analyses, respectively. Due to a positive bias (mean bias 50.26; 95% CI 36.24-64.29), a higher threshold was needed in multiple myeloma patients (HPC 132 × 10/L), saving only 24% of flow cytometry analyses.
Conclusion: When the HPC count is above the corresponding threshold, apheresis could be safely initiated without waiting for the flow cytometry result, thereby reducing time-to-decision. Lower HPC values, however, require confirmation by flow cytometry.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/trf.17937 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Chronic Myelomonocytic Leukemia with Central Nervous System Involvement in a Dog.
J Am Anim Hosp Assoc
January 2025
From Veterinary Neurological Center "La Fenice," Selargius, Italy (I.T., F.T., A.G.).
An 8 yr old, male, mixed-breed dog was presented with a 2 mo history of progressive weakness, worsened in the last 2 days before examination. Neurological examination revealed ambulatory tetraparesis, ataxia, and proprioceptive deficits in all four limbs. Menace response was reduced in the right eye and discomfort was detected on neck manipulation.
View Article and Find Full Text PDFElevated plasma molybdenum level increases the risk of premature ovarian insufficiency through vascular endothelial injury.
Hum Reprod
January 2025
The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Study Question: Is elevated plasma molybdenum level associated with increased risk for idiopathic premature ovarian insufficiency (POI)?
Summary Answer: Elevated plasma molybdenum level is associated with an increased risk of idiopathic POI through vascular endothelial injury and inhibition of granulosa cell proliferation.
What Is Known Already: Excessive molybdenum exposure has been associated with ovarian oxidative stress in animals but its role in the development of POI remains unknown.
Study Design, Size, Duration: Case-control study of 30 women with idiopathic POI and 31 controls enrolled from August 2018 to May 2019.
Malian field isolates provide insight into Plasmodium malariae intra-erythrocytic development and invasion.
PLoS Negl Trop Dis
January 2025
Malaria Research and Training Center (MRTC), Université des Sciences, des Techniques et des Technologies de Bamako (USTTB), Bamako, Mali.
Plasmodium malariae is the third most prevalent human malaria parasite species and contributes significantly to morbidity. Nevertheless, our comprehension of this parasite's biology remains limited, primarily due to its frequent co-infections with other species and the lack of a continuous in vitro culture system. To effectively combat and eliminate this overlooked parasite, it is imperative to acquire a better understanding of this species.
View Article and Find Full Text PDFSynergistic Inhibition of Breast Carcinoma Cell Proliferation by Quercetin and Sulforaphane via Activation of the ERK/MAPK Pathway.
Cell Biochem Biophys
January 2025
Pharmacy Administration Office, The Third Hospital of Nanchang City, Jiangxi Province, Nanchang, Jiangxi, China.
In the contemporary era of drug discovery, herbal treatments have demonstrated an unparalleled ability to produce anticancer drugs. An important part of the therapy of cancer is the use of plants and their by-products via analogues, which alter the tumor microenvironment and several signaling pathways. The objective of the current investigation was to conclude the rate at which the herbal medications quercetin (QT) and sulforaphane (SFN) repressed the growth of breast carcinoma cells in MDA-MB-231 by preventing the ERK/MAPK signaling systems.
View Article and Find Full Text PDFModeling the lymph node stromal cells in oral squamous cell carcinoma: insights into the stromal cues in nodal metastasis.
Hum Cell
January 2025
Integrated Head and Neck Oncology Program (DSRG-5), Mazumdar Shaw Medical Foundation, Narayana Health, Bangalore, India.
The study explores the development and characterization of lymph node stromal cell cultures (LNSCs) from patients with oral squamous cell carcinoma (OSCC), highlighting the importance of understanding tumor-node cross-talk for effective prognostic and therapeutic interventions. Herein, we describe the development and characterization of primary lymph node stromal cells (LNSCs, N = 14) from nodes of metastatic and non-metastatic OSCC patients. Primary cultures were established by the explant method from positive (N + ; N = 2), and negative nodes (N0; N = 4) of the metastatic patients (N = 3) as well as negative (N0; N = 8) nodes from non-metastatic (N = 4) patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!